Drug intelligence / Profile preview

D10-mAb1

Development stage: Preclinical
Lead developer: D-10 Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

D10-mAb1 is a monoclonal antibody targeting CD47, currently in preclinical development by D-10 Therapeutics for the treatment of Sickle Cell Disease (SCD). CD47, often referred to as a 'don't eat me' signal, is a cell surface protein that inhibits phagocytosis by interacting with SIRPα on macrophages. In the context of Sickle Cell Disease, targeting the CD47 pathway is intended to modulate the survival and clearance of red blood cells, potentially addressing the underlying pathophysiology of the disease and reducing complications such as vaso-occlusive crises.

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on D10-mAb1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D10-mAb1.

Explore the full profile